Acquired Orphan Blood Diseases Therapeutics Market to 2019 – Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Acquired Orphan Blood Diseases – Introduction 9
2.1 Overview 9
3 Acquired Orphan Blood Diseases – Therapeutic Landscape 10
3.1 Paroxysmal Nocturnal Hemoglobinuria 10
3.1.1 Disease Overview 10
3.1.2 Revenues 12
3.1.3 Revenue Analysis by Country 13
3.1.4 Annual Cost of Therapy 17
3.1.5 Treatment Usage Patterns 18
3.1.6 Marketed Products 19
3.1.7 Market Drivers 20
3.1.8 Market Restraints 20
3.2 Paroxysmal Nocturnal Hemoglobinuria: Research and Development Pipeline 21
3.2.1 Overview 21
3.2.2 Trends in Paroxysmal Nocturnal Hemoglobinuria Pipeline 23
3.2.3 Promising Pipeline Molecules 24
3.2.4 Key Takeaway 24
3.3 Idiopathic Thrombocytopenic Purpura 25
3.3.1 Disease Overview 25
3.3.2 Revenues 27
3.3.3 Revenue Analysis by Country 28
3.3.4 Annual Cost of Therapy 32
3.3.5 Treatment Usage Patterns 33
3.3.6 Marketed Products 34
3.3.7 Market Drivers 34
3.3.8 Market Restraints 34
3.4 Idiopathic Thrombocytopenic Purpura: Research and Development Pipeline 35
3.4.1 Overview 35
3.4.2 Pipeline by Clinical Phase of Development 36
3.4.3 Trends in Idiopathic Thrombocytopenic Purpura Pipeline 40
3.4.4 Promising Pipeline Molecules 41
3.4.5 Key Takeaway 43
3.5 Myelodysplastic Syndrome 44
3.5.1 Disease Overview 44
3.5.2 Revenues 45
3.5.3 Revenue Analysis by Country 46
3.5.4 Annual Cost of Therapy 50
3.5.5 Treatment Usage Patterns 51
3.5.6 Marketed Products 52
3.5.7 Market Drivers 53
3.5.8 Market Restraints 53
3.6 Myelodysplastic Syndrome: Research and Development Pipeline 54
3.6.1 Overview 54
3.6.2 Pipeline by Clinical Phase of Development 55
3.6.3 Trends in Myelodysplastic Syndrome Pipeline 80
3.6.4 Promising Pipeline Molecules 83
3.6.5 Key Takeaway 83
3.7 Myelofibrosis 84
3.7.1 Disease Overview 84
3.7.2 Revenues 85
3.7.3 Revenue Analysis by Country 86
3.7.4 Annual Cost of Therapy 90
3.7.5 Treatment Usage Patterns 91
3.7.6 Marketed Products 92
3.7.7 Market Drivers 92
3.7.8 Market Restraints 92
3.8 Myelofibrosis: Research and Development Pipeline 93
3.8.1 Overview 93
3.8.2 Pipeline by Clinical Phase of Development 94
3.8.3 Trends in Myelofibrosis Pipeline 99
3.8.4 Promising Pipeline Molecules 101
3.8.5 Key Takeaway 101
3.9 Polycythemia Vera 102
3.9.1 Disease Overview 102
3.9.2 Revenues 103
3.9.3 Revenue Analysis by Country 104
3.9.4 Annual Cost of Therapy 108
3.9.5 Treatment Usage Patterns 109
3.9.6 Marketed Products 110
3.9.7 Market Drivers 111
3.9.8 Market Restraints 111
3.10 Polycythemia Vera: Research and Development Pipeline 112
3.10.1 Overview 112
3.10.2 Pipeline by Clinical Phase of Development 113
3.10.3 Trends in Polycythemia Vera Pipeline 116
3.10.4 Promising Pipeline Molecules 118
3.10.5 Key Takeaway 118
4 Acquired Orphan Blood Diseases – Strategic Consolidations 119
4.1 Overview 119
4.1.1 Segmentation by Year 119
4.1.2 Segmentation by Indication 119
4.1.3 Segmentation by Geography 120
4.1.4 Segmentation by Deal Value 120
4.1.5 Segmentation by Deal Type 121
4.2 Major Mergers and Acquisitions 121
4.3 Major Licensing Agreements 122
5 Acquired Orphan Blood Diseases – Appendix 123
5.1 Abbreviations 123
5.2 Sources 123
5.3 Research Methodology 124
5.3.1 Coverage 124
5.3.2 Secondary Research 124
5.3.3 Primary Research 125
5.3.4 Therapeutic Landscape 125
5.3.5 Geographical Landscape 128
5.3.6 Pipeline Analysis 128
5.3.7 Competitive Landscape 128
5.3.8 Expert Panel Validation 128
5.4 Contact Us 128
5.5 Disclaimer 128